Arrieta AC, et al. - In this randomized multicenter study, researchers compared the safety and effectiveness of intravenous daptomycin with standard-of-care (SOC) for the treatment of staphylococcus aureus bacteremia in 1- to 17-year-old patients. In children with staphylococcal bacteremia, once-daily, age-appropriate daptomycin was well tolerated and effectiveness was similar to SOC. It was concluded that daptomycin in age-adjusted doses was a safe treatment alternative in this setting.